Gaining an Understanding of Pneumocystosis in Wales

Author:

Ayling-Smith Jonathan12ORCID,Backx Matthijs3ORCID,Grant Elizabeth1,Dhillon Rishi3,Duckers Jamie4ORCID,Hood Kerenza2ORCID,White P. Lewis3ORCID

Affiliation:

1. Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff CF14 4XW, UK

2. College of Biomedical and Life Sciences, Cardiff University, Cardiff CF10 3AT, UK

3. Public Health Wales, Cardiff CF10 4BZ, UK

4. All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Penarth CF64 2XX, UK

Abstract

Pneumocystis pneumonia (PcP) is a serious complication of many significant immunocompromising conditions. Prior incidence estimates in Wales are based on PcP’s presentation in the HIV and transplant populations. The objectives were to describe the incidence of PcP in Wales using laboratory reporting measures and assess the impact of underlying immunosuppression cause on mortality. All positive PCR results for PcP between 2015 and 2018 were identified. The total number of unique positives with clinical and radiological correlation was 159 patients, a mean of 39.75 annually. The healthcare records of these patients were reviewed. The mortality at one month was 35.2% and 49.1% at one year. HIV remains the commonest cause of immunosuppression but has lower mortality than non-HIV conditions (12% vs. 59% at one year, p < 0.00001). Non-HIV conditions were categorised as life-threatening and non-life threatening but had a non-significant mortality (66% vs. 54%; p = 0.149), highlighting the negative impact of PcP. An incidence of PcP in Wales of 1.23–1.26 cases per 100,000 has been identified, 32–35% greater than the upper limit previously estimated. There is high mortality in non-HIV patients regardless of immunosuppression cause. A heightened awareness of PcP in these groups will hasten diagnosis and potentially improve mortality.

Publisher

MDPI AG

Subject

Plant Science,Ecology, Evolution, Behavior and Systematics,Microbiology (medical)

Reference24 articles.

1. White, P.L., Price, J.S., and Backx, M. (2018). Therapy and Management of Pneumocystis jirovecii Infection. J. Fungi, 4.

2. WHO (2022). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action, World Health Organization.

3. Estimating the Burden of Invasive and Serious Fungal Disease in the United Kingdom;Pegorie;J. Infect.,2017

4. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies;Davis;Clin. Microbiol. Rev.,2020

5. Evolving Epidemiology of Pneumocystis Pneumonia: Findings from a Longitudinal Population-Based Study and a Retrospective Multi-Center Study in Germany;Kolbrink;Lancet Reg. Health-Eur.,2022

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3